Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

Panelists discuss how black box warnings on IV iron products, particularly regarding hypersensitivity reactions, influence their risk assessment, patient selection, monitoring protocols, and facility ...